نتایج جستجو برای: posaconazole

تعداد نتایج: 1355  

Journal: :Therapeutics and Clinical Risk Management 2008
Stefan Langner Philipp B Staber Peter Neumeister

The rising incidence of invasive fungal infections due to the expanding population of immunocompromised hosts and the increasing prevalence of fungal resistance has led to the need for novel antifungal agents. Posaconazole, a new member of the triazole class has demonstrated in vitro activity against a broad spectrum of fungi and clinical activity against various fungal pathogens, including Asp...

2012
Dalia A. Hamdy Hager El-Geed Samah El-Salem Manal Zaidan

Coadministration of azoles and vincristine has been shown to increase vincristine neurotoxic effects due to the inhibition of cytochrome P450 (CYP) isoform 3A4, for which vincristine is a substrate. Despite the absence of any casual relationship between seizure and coadministration of azoles, few case reports of vincristine-induced seizure have been documented after coadministration of fluconaz...

Journal: :The Journal of antimicrobial chemotherapy 2004
Steve Hernandez Gloria M Gonzalez Dora I McCarthy Arnaldo Lopes Colombo Laura K Najvar Rosie Bocanegera John R Graybill

OBJECTIVE Amphotericin B failure is frequently seen in patients with candidaemia caused by Candida rugosa. We evaluated amphotericin B, fluconazole, posaconazole and voriconazole as alternative treatments against infection in mice with two isolates of C. rugosa. METHODS Neutropenic mice were inoculated intravenously with C. rugosa. Amphotericin B, fluconazole, posaconazole and voriconazole we...

Journal: :The Journal of asthma : official journal of the Association for the Care of Asthma 2012
Livingstone Chishimba Robert M Niven John Cooley David W Denning

Rationale and objectives. Severe asthma with fungal sensitization (SAFS) and allergic bronchopulmonary aspergillosis (ABPA) are progressive allergic fungal lung diseases whose effective treatment remains to be established. Current treatment with itraconazole is associated with a 40% failure rate and adverse events (AEs). We assessed the effect of voriconazole or posaconazole as second- and thir...

Journal: :Antimicrobial agents and chemotherapy 2004
D Andes K Marchillo R Conklin Gopal Krishna Farkad Ezzet Anthony Cacciapuoti David Loebenberg

Previous in vivo studies have characterized the pharmacodynamic characteristics of two triazole compounds, fluconazole and ravuconazole. These investigations demonstrated that the 24-h area under the concentration-time curve (AUC)/MIC ratio is the critical pharmacokinetic-pharmacodynamic (PK-PD) parameter associated with treatment efficacy. Further analysis demonstrated that a free-drug triazol...

2013
Samin Alavi Maryam Ebadi

Dear Editor, An 8-year-old boy, a known case of T-cell acute lymphoblastic leukemia (ALL), was admitted for an episode of fever and neutropenia. In preliminary investigations and based on chest computed tomography results, he was diagnosed as having pulmonary fungal infection, which was treated with conventional amphotericin B. Two weeks later, chest computed tomography showed no improvement of...

Journal: :Antimicrobial agents and chemotherapy 2012
Masato Tashiro Koichi Izumikawa Asuka Minematsu Katsuji Hirano Naoki Iwanaga Shotaro Ide Tomo Mihara Naoki Hosogaya Takahiro Takazono Yoshitomo Morinaga Shigeki Nakamura Shintaro Kurihara Yoshifumi Imamura Taiga Miyazaki Tomoya Nishino Misuzu Tsukamoto Hiroshi Kakeya Yoshihiro Yamamoto Katsunori Yanagihara Akira Yasuoka Takayoshi Tashiro Shigeru Kohno

We investigated the triazole, amphotericin B, and micafungin susceptibilities of 196 A. fumigatus clinical isolates in Nagasaki, Japan. The percentages of non-wild-type (non-WT) isolates for which MICs of itraconazole, posaconazole, and voriconazole were above the ECV were 7.1%, 2.6%, and 4.1%, respectively. A G54 mutation in cyp51A was detected in 64.2% (9/14 isolates) and 100% (5/5 isolates) ...

2015
Ariane Gomes Paixão Maria Clara Gutierrez Galhardo Rodrigo Almeida-Paes Estevão Portela Nunes Marcelo Luiz Carvalho Gonçalves Gisele Larias Chequer Cristiane da Cruz Lamas

Sporotrichosis is an infection caused by a dimorphic fungus of the Sporothrix schenckii complex. Host immunity is an important factor in the clinical manifestations of the disease. Deeply immunocompromised individuals, especially those infected with the Human Immunodeficiency Virus (HIV) and T CD4 counts < 350 cells/ul lymphocytes, may present with the systemic form of sporotrichosis. This repo...

2011
Erica Finolezzi

In this article, the pharmacological, microbiological and clinical development progress from Phase II and III clinical trials with the new generation triazoles albaconazole, isavuconazole, posaconazole, ravuconazole and voriconazole are reviewed. These drugs exhibit a favorable toxicity profile and possess high activity against resistant and emerging fungal pathogens. Pharmacokinetic may be aff...

Journal: :Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008
Oliver A Cornely Andrew J Ullmann

Correspondence Table 1. Numbers needed to treat (NNTs) with posaconazole prophylaxis to prevent invasive fungal infection and death.

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید